Notable Price Action: What Next for Atara Biotherapeutics Inc Stock After Today’s Huge Decline?

Notable Price Action: What Next for Atara Biotherapeutics Inc Stock After Today's Huge Decline?

The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) is a huge mover today! The stock decreased 4.35% or $0.93 during the last trading session, hitting $20.46. About 110,928 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has risen 15.66% since March 1, 2016 and is uptrending. It has outperformed by 3.44% the S&P500.
The move comes after 5 months negative chart setup for the $610.30 million company. It was reported on Oct, 4 by We have $19.44 PT which if reached, will make NASDAQ:ATRA worth $30.52 million less.

Analysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings on November, 3. They expect $-0.69 EPS, down 60.47% or $0.26 from last year’s $-0.43 per share. After $-0.66 actual EPS reported by Atara Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.

Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage

Out of 5 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 3 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 60% are positive. Atara Biotherapeutics has been the topic of 12 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The stock has “Sell” rating given by Citigroup on Monday, August 22. As per Tuesday, December 15, the company rating was maintained by JMP Securities. As per Thursday, September 15, the company rating was downgraded by Goldman Sachs. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, September 9. As per Friday, September 25, the company rating was initiated by JMP Securities. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) earned “Sell” rating by Citigroup on Tuesday, December 15. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. Goldman Sachs initiated it with “Neutral” rating and $38 target price in Wednesday, November 18 report. Citigroup maintained the stock with “Sell” rating in Friday, August 19 report. The company was initiated on Friday, October 9 by William Blair.

According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”

Insitutional Activity: The institutional sentiment increased to 3.36 in 2016 Q2. Its up 2.20, from 1.16 in 2016Q1. The ratio increased, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Fmr Limited Com has 3.13 million shares for 0.01% of their US portfolio. Manufacturers Life Ins The last reported 0% of its portfolio in the stock. 12 West Cap Management Ltd Partnership owns 398,700 shares or 1.45% of their US portfolio. Dekabank Deutsche Girozentrale holds 16,200 shares or 0% of its portfolio. Barclays Public Ltd Com has 4,803 shares for 0% of their US portfolio. California State Teachers Retirement System holds 0% or 48,704 shares in its portfolio. Great West Life Assurance Commerce Can has 1,654 shares for 0% of their US portfolio. Vident Investment Advisory Limited Liability accumulated 0.1% or 32,879 shares. Redmile Ltd Llc accumulated 5.18% or 2.41 million shares. Vanguard Gru has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Invesco accumulated 110,197 shares or 0% of the stock. Eagle Asset Mgmt holds 0.15% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 972,592 shares. Moreover, Blackrock Fund has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 913,922 shares. Harbourvest Prtnrs Ltd Com last reported 0.11% of its portfolio in the stock. Tiaa Cref Management Limited Liability reported 71,630 shares or 0% of all its holdings.

Insider Transactions: Since April 11, 2016, the stock had 0 insider buys, and 15 insider sales for $1.88 million net activity. The insider Ciechanover Isaac E. sold $26,159. $62,918 worth of shares were sold by Clark Mitchall G. on Monday, May 16. $86,344 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by Soffer Gad on Monday, May 16. Gallagher Carol Giltner sold $18,897 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Monday, May 16. 1,346 shares were sold by Haqq Christopher, worth $30,041. $85,079 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares were sold by MCGRATH JOHN.

More news for Atara Biotherapeutics Inc (NASDAQ:ATRA) were recently published by:, which released: “Virtual Stock Exchange” on October 17, 2014.‘s article titled: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” and published on December 14, 2015 is yet another important article.

ATRA Company Profile

Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment